A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye : ARISE-2

Trial Profile

A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye : ARISE-2

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Thymosin-beta-4 (Primary)
  • Indications Dry eyes
  • Focus Therapeutic Use
  • Acronyms ARISE-2
  • Sponsors ReGenTree
  • Most Recent Events

    • 27 Jul 2017 Status changed from recruiting to active, no longer recruiting, according to a RegeneRx Biopharmaceuticals media release.
    • 09 Nov 2016 According to a Regenex Pharmaceutical media release, company plans to complete and report patient data in in Q4 2017.
    • 09 Nov 2016 Status changed from not yet recruiting to recruiting, as per RegeneRx Biopharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top